Home » Posts tagged 'sharesoc growth company seminar'

Tag Archives: sharesoc growth company seminar

Open Orphan #ORPH presents at ShareSoc Growth Company Seminar, Manchester

Open Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study servicesand has Europe’s only 24 bedroom quarantine clinic with onsite virology lab in Queen Mary’s Hospital London, is pleased to announce that the Company will be attending and presenting at the ShareSoc Growth Company Seminar on February 25, 2020 at DoubleTree by Hilton Hotel, One Piccadilly Place, 1 Auburn Street, Manchester M1 3DG.

Cathal Friel, Open Orphan’s Executive Chairman will be presenting from 18:40 onwards to update existing and potential investors on the Company’s business plans for 2020.

The event will provide an opportunity for investors to hear about the progress being made by the Company following the acquisition of hVIVO and the potential for Open Orphan as it moves rapidly forward rapidly.  hVIVO, is a world leader in the provision of viral challenge studies, vaccine and viral laboratory services ,and supports product development for customers developing antivirals, vaccines and respiratory therapeutics, all of which are particularly relevant and topical in the environment of heightened awareness in light of  the current outbreak of coronavirus disease (COVID-19).It also has Europe’s only commercial 24 bed quarantine clinic and on site virology laboratory at Queen Mary’s Hospital in London.

A link to our investor presentation is already available on our website  at https://www.openorphan.com/sites/openorphan/files/Open_Orphan_Investor_Deck_0120_1.pdf

Additionally, a link to the video of Open Orphan’s presentation will be made available on the Company website following the event.

For further information on the Shares Investor Evening and registration, please visit the event website https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-manchester-25-february-2020/

No new material information will be disclosed at this event.

Enquiries:

Open Orphan Plc Tel: +353 1 5499 341

Cathal Friel, Executive Chairman                                                                        +353 (0)1 644 0007

Trevor Phillips, Chief Executive Officer                                                              +44 (0)20 7347 5350

Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363
Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

Notes to Editors:

Open Orphan is a rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services and viral laboratory services. It has Europe’s only 24-bedroom quarantine clinic with onsite virology lab in Queen Mary’s Hospital London. hVIVO supports product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the Coronavirus in 2020. The company also has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models.  No other company in the world has such a portfolio, with only two competitors globally having 1 challenge study model each. 

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.